Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23934301 | 0.93 | TDP1 (0.38) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL15798547 | 0.86 | GAA (0.44) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL2721040 | 0.84 | — | — | |
| SCHEMBL2778453 | 0.84 | TRPA1 (0.41) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL24791075 | 0.82 | FFAR4 (0.38) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL3307079 | 0.82 | MGAM (0.38) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL1837169 | 0.81 | BRD4 (0.42) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1881523 | 0.80 | ALDH1A1 (0.46) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL1439129 | 0.80 | TDP1 (0.48) | MGAMGAASIMGAM2TRPA1 | |
| SCHEMBL169393 | 0.80 | ALDH1A1 (0.42) | MGAMGAASIMGAM2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880163-A1 | USE OF 1-ETHYL-4,4-DIMETHYL-CYCLOHEXANE DERIVATIVES AS FRAGRANCES | Symrise AG (DE) | 2021-09-22 | — | — | EP | claimed |
| EP-3880163-A1 | USE OF 1-ETHYL-4,4-DIMETHYL-CYCLOHEXANE DERIVATIVES AS FRAGRANCES | Symrise AG (DE) | 2021-09-22 | — | — | EP | disclosed |
| CN-112969444-A | Use of 1-ethyl-4, 4-dimethylcyclohexane derivatives as fragrance substances | 西姆莱斯有限公司 | 2021-06-15 | — | — | CN | disclosed |
| US-9546138-B2 | Pyridone derivatives and uses thereof in the treatment of tuberculosis | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| US-9546138-B2 | Pyridone derivatives and uses thereof in the treatment of tuberculosis | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| US-9546138-B2 | Pyridone derivatives and uses thereof in the treatment of tuberculosis | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2931716-B1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| EP-2931716-B1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| EP-2931716-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | Novartis AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| CN-104837827-A | Pyridone derivatives and their use in the treatment of tuberculosis | NOVARTIS AG | 2015-08-12 | — | — | CN | disclosed |
| WO-2014093606-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014093606-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| EP-1606244-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004037769-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1077940-A1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | COASY, PLPBP, ACSS2 | MGAM 937/4885GAA 1619/4885SI 3303/4885 |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | MGAM 4395/4885GAA 1464/4885SI 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.